Aethlon Medical (AEMD) Q1 FY27 earnings call

Aethlon Medical continues to advance its investigational Hemopurifier platform, with the Australian oncology trial entering its final cohort and showing encouraging preliminary biomarker data. The company also expanded preclinical research into Long COVID and other diseases, while strengthening its financial position to support ongoing activities. The focus remains on clinical development, platform expansion, and disciplined resource management as it navigates regulatory pathways for its technology.